GLI1 and skin basal cell carcinoma: By contrast, despite the superior pharmacological properties of GLI inhibitors, arsenic trioxide remains the sole GLI inhibitor that has been investigated clinically in Hh pathway-active cancers such as BCC (NCT01791894, completed) [153].